Determined by its ability to induce alkaline phosphatase production by ATDC-5 cells. The expected EC50 for this effect is 100-144 ng/ml.
BMP-2 Protein, Human/Mouse/Rat
BMP-2 Protein, Human/Mouse/Rat
Price:
Regular price
$150 USD
Regular price
Sale price
$150 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Synonyms | Bone morphogenetic protein 2, BMP-2, Bone morphogenetic protein 2A (BMP-2A) |
| Accession | P12643 |
| Amino Acid Sequence | Leu284-Arg396 |
| Expression System | CHO |
| Molecular Weight | 14-16 kDa (Reducing) |
| Purity | >95% by SDS-PAGE. |
| Endotoxin | <0.1EU/μg |
| Conjugation | Unconjugated |
| Tag | No Tag |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | 4mM HCl |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in Reconstitution Buffer after rapid centrifugation. |
| Stability & Storage | ·12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
| Reference | Bone: formation by autoinduction. Science 150, 893–899 (1965). |
Background
Bone morphogenetic protein 2 (BMP-2) is a multifunctional growth factor belonging to the transforming growth factor-β (TGF-β) superfamily. The osteoinductive activity of bone-derived proteins was first described by Marshall Urist in 1965. As one of the most potent osteoinductive factors known, BMP-2 initiates the differentiation of mesenchymal stem cells into osteoblasts and chondrocytes, playing essential roles in embryonic skeletal development, bone remodeling, and fracture healing.
In the biomedical industry, rhBMP-2 received FDA approval in 2002 and is commercially available as the Infuse™ Bone Graft system, delivered via an absorbable collagen sponge carrier. Industrial applications are predominantly focused on spinal fusion surgeries, where rhBMP-2 has demonstrated fusion rates comparable to or higher than autologous bone grafts. Additional clinical indications include open tibial fractures, maxillofacial reconstruction, sinus augmentation, and treatment of femoral head necrosis. However, clinical use is constrained by dose-dependent complications including inflammation, ectopic ossification, osteolysis, and concerns regarding cost and safety.
Picture
Picture
Bioactivity
Measured by its ability to induce BMP-2 responsive firefly luciferase reporter activity in HEK293T human embryonic kidney cells. The expected EC50 for this effect is 0.38-3.3 ng/ml.
SDS-PAGE
2μg (R: reducing condition, N: non-reducing condition).
